The ECHS Central Organisation is located at Delhi and functions under the Chief of Staff Committee (COSC) through AG and DGDC&W in Army HQ. The Central organisation is headed by Managing Director, ECHS, a serving Major General. There are 28 Regional Centres ECHS and 426 ECHS Polyclinics. ECHS is also an attached office of Dept of Ex-Servivemen Welfare (DoESW), Ministry of Defence (MoD) as are Directorate General Resettlement(DGR) and Kendriya Sainik Board (KSB).
1st Class Post Graduate Degree, including the integrated PG Degree in Biotechnology, Life Sciences/Applied Biology / Life Sciences OR Second Class Post Graduate degree including the integrated PG degrees in Sciences with Ph.D. in Biotechnology / Life Sciences / Applied Biology
First class post graduate degree with including integrated post graduate degree with 1 year of experience ; Second class post graduate degree with PhD or 3 years of experience
Strong background in Chemistry, Life Sciences, Environmental Science, Instrumentation, data acquisition systems and computers. Ability to handle repairing and maintenance work of the instruments.
M. Sc. or M. Pharm. or M. Tech. in Basic or Applied Sciences, Engineering or related areas. Students who have appeared for the final year, semester examinations are also eligible, provided that the degree will be granted by the time of joining.
Graduate, Post Graduate Degree Professional Course selected through national level examination conducted by Central Government or the agencies ICMR, DBT, DAE, DST, IIT, IISER, NISER, IISc etc. qualified.
Promote pharma product portfolio to healthcare professionals and institutions. Develop and maintain strong relationships with doctors, pharmacists, and key opinion leaders.
Degree in a Medical, Pharma, scientific discipline or a related Life science degree, with substantial project management or clinical trials and drug development experience.
Lead the development and execution of local medical strategies aligned with global and franchise objectives. Identify strategic drivers and shape the patient journey and stakeholder engagement plans.
Deep within Assam’s vibrant ecosystem, scientists at the Institute of Advanced Study in Science & Technology (IASST), Guwahati, have uncovered a remarkable paradox: some of nature’s most toxic flora may hold potent therapeutic potential. This revelation, emerging from extensive research into poisonous plant species, could herald a paradigm shift in natural product–based medicine.
Emcure Pharmaceuticals has announced that its Board of Directors has approved a proposal to acquire the remaining 20.42% minority stake in its subsidiary, Zuventus Healthcare Ltd. The acquisition will result in Zuventus becoming a wholly owned subsidiary of Emcure.
Eli Lilly and Company announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes
An Engineering Degree, B.Pharma, MBA from a recognised University. Central Medical Services Society, a Central Procurement Agency of Ministry of Health and Family Welfare
MS Pharm, MPharm, M. Tech. Pharm, M.Sc. Chemistry specialized in Medicinal Chemistry or Pharmaceutical chemistry or Process Chemistry or Organic Chemistry, M.Pharma with two year of relevant experience.